Personal executive stock portfolios distort the federal regulation of metabolic medicine.
Highly irregular regulatory approvals, compounding bans, and single-patient expanded access pathways occur in direct lockstep with executive-level equity holdings in dominant pharmaceutical makers.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Federal ethics disclosures link high-level policy support for GLP-1 coverage directly to underlying personal equity positions in a major manufacturer.
Ethical concerns have emerged over the timing of favorable federal policies advancing Eli Lilly's pipeline and personal stock purchases by the administration.
Ethics filings indicate that administration officials acquired Eli Lilly equity immediately before the government expedited approval of its drug and cracked down on competitors.